Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04)

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1349-1355

  Mamounas, Eleftherios ^a   Wieand, Samuel ^a   Wolmark, Norman ^a   Bear, Harry D ^a   Atkins, James N ^a   Song, Kyunghee ^a   Jones, Judy ^a   Rockette, Howard ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; SEMUSTINE; VINCRISTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032949446     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1349     Document Type: Article

References (21)

1. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
2. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma N Engl J Med 322:352-358, 1990
3. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
4. Moertel CG, Fleming TR, Macdonald JS, et al: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13:2936-2943, 1995
5. Mamounas EP, Rockette H, Jones J, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs Dukes' C colon cancer: Results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). Proc Am Soc Clin Oncol 15:205a, 1996 (abstr 461)
6. Wolmark N, Fisher B, Rockette H, et al: Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 80:30-36, 1988
7. Wolmark N, Rockette H, Wickerham DL, et al: Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol 8:1466-1475, 1990
8. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
9. Wolmark N, Rockette H, Mamounas EP, et al: The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon. Proc Am Soc Clin Oncol 15:205a, 1996 (abstr 460)
10. Dukes CE: The classification of cancer of the rectum J Pathol 35:323-332, 1932
11. Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chron Dis 8:699-712, 1958
12. Mantel N, Haenszel W: Statistical aspects of the analysis of the data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
13. Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies - Liver Infusion Meta-Analysis Group. J Natl Cancer Inst 89:497-505, 1997
14. Erlichman C, Marsoni S, Seitz JF, et al: Event free and overall survival is increased by FUFA in resected B colon cancer: A pooled analysis of five randomized trials (RCTS). Proc Am Soc Clin Oncol 16:280a, 1997 (abstr 991)
15. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356-1363, 1999
16. Jen J, Kim H, Piantadosi S, et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213-221, 1994
17. Bronner CE, Baker SM, Morrison PT, et al: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258-261, 1994
18. Nicolaides NC, Papadopoulos N, Liu B, et al: Mutations in two PMS homologues in hereditary nonpolyposis colon cancer Nature 371:75-80, 1994
19. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12-2640-2647, 1994
20. Bosari S, Viale G, Possi P, et al: Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681-687, 1994
21. Zeng Z-S, Sarkis AS, Zhang Z-F, et al: p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12:2043-2050, 1994